Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Liver Cirrhosis Pipeline Report 2016: Therapeutics Review of 9 Companies & 15 Molecules - Research and Markets

Research and Markets
Posted on: 11 Oct 16

Research and Markets has announced the addition of the "Liver Cirrhosis - Pipeline Review, H2 2016" report to their offering.

Liver Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Liver Cirrhosis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Liver Cirrhosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Liver Cirrhosis - Overview
  5. Pipeline Products for Liver Cirrhosis - Comparative Analysis
  6. Liver Cirrhosis - Therapeutics under Development by Companies
  7. Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
  8. Liver Cirrhosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Liver Cirrhosis - Products under Development by Companies
  13. Liver Cirrhosis - Products under Investigation by Universities/Institutes
  14. Liver Cirrhosis - Companies Involved in Therapeutics Development
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Galectin Therapeutics, Inc.
  • Human Stem Cells Institute
  • Nimbus Therapeutics, LLC
  • Ocera Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • S-Evans Biosciences, Inc.
  • Stelic Institute & Co., Inc.

For more information about this report visit http://www.researchandmarkets.com/research/v7dhbp/liver_cirrhosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005835/en/

Business Wire
www.businesswire.com

Last updated on: 11/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.